West Pharmaceutical Services, Inc.
WST
$303.74
-$8.33-2.67%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.23% | 6.25% | 4.92% | 2.90% | -1.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.23% | 6.25% | 4.92% | 2.90% | -1.12% |
| Cost of Revenue | 8.28% | 3.98% | 3.78% | 3.56% | 3.04% |
| Gross Profit | 16.83% | 10.57% | 7.05% | 1.70% | -8.15% |
| SG&A Expenses | 20.25% | 16.36% | 6.78% | -0.89% | -5.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -233.33% | 44.44% | -52.63% | 33.33% | -25.00% |
| Total Operating Expenses | 9.94% | 5.91% | 4.15% | 2.75% | 1.52% |
| Operating Income | 16.19% | 7.60% | 7.88% | 3.43% | -10.14% |
| Income Before Tax | 17.60% | 2.52% | 1.98% | -2.54% | -14.83% |
| Income Tax Expenses | 23.44% | 13.12% | 18.92% | 20.84% | 0.09% |
| Earnings from Continuing Operations | 16.16% | 0.20% | -1.58% | -7.09% | -17.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.16% | 0.20% | -1.58% | -7.09% | -17.85% |
| EBIT | 16.19% | 7.60% | 7.88% | 3.43% | -10.14% |
| EBITDA | 14.99% | 8.16% | 8.24% | 4.92% | -6.06% |
| EPS Basic | 17.11% | 1.17% | -0.26% | -5.50% | -16.35% |
| Normalized Basic EPS | 17.19% | 8.65% | 9.17% | 4.29% | -9.31% |
| EPS Diluted | 17.37% | 1.45% | 0.32% | -4.82% | -15.83% |
| Normalized Diluted EPS | 17.54% | 9.05% | 9.60% | 4.78% | -8.89% |
| Average Basic Shares Outstanding | -0.79% | -0.96% | -1.30% | -1.59% | -1.76% |
| Average Diluted Shares Outstanding | -1.09% | -1.32% | -1.69% | -2.04% | -2.20% |
| Dividend Per Share | 4.88% | 4.94% | 5.00% | 5.06% | 5.13% |
| Payout Ratio | -0.11% | 0.03% | 0.05% | 0.11% | 0.26% |